The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.